Eye drop licence suspended over safety concern

NEW DELHI:  The Drug Controller General of India (DCGI) on Wednesday suspended the licence to manufacture and market PresVu, an eye drop that claims to reduce the need for reading glasses in people with Presbyopia – a common age-related problem that makes it difficult to focus on close objects.

Govt sources said the action has been taken because the makers of the eye drop, Entod Pharmaceuticals, were involved in unauthorised promotion of the product which raised doubt on its unsafe use by patients and safety concern for the public.

“The promotion had raised concern about its use like OTC drugs whereas it is approved as a prescription only drug,” govt sources said.
Entod Pharmaceuticals, on the other hand, denied making any unethical or false presentation of facts with regards to the PresVu eye drops and said it will challenge the suspension order in the court of law to get justice.

“Our approval by DCGI was based on a valid controlled clinical trial in 234 patients which was successful in showing efficacy and safety of these eye drops in patients of Presbyopia, who used these drops without eyeglasses and could read additional lines on Snellen’s chart which is yardstick of near vision impairment,” the company said in its statement.

“Such eye drops with the same active ingredient and same concentration have been approved by the US FDA and marketed in the US for the last three years without any serious complications. FDA didn’t take any action on the companies marketing the same in the US,” the statement added.

Related Posts

WHO launches new primary health care course to strengthen health systems globally

Health is a human right – yet not everyone can access the health services they need, when and where they need them, without financial hardship. Primary health care (PHC) provides…

Ayurveda needs stronger evidence, safety monitoring for market adoption, says CCRAS

Bengaluru: The Central Council for Research in Ayurvedic Sciences (CCRAS) has called for stronger scientific evidence, safety monitoring and translation of research into market-ready technologies to improve the credibility and…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

WHO launches new primary health care course to strengthen health systems globally

WHO launches new primary health care course to strengthen health systems globally

Ayurveda needs stronger evidence, safety monitoring for market adoption, says CCRAS

Ayurveda needs stronger evidence, safety monitoring for market adoption, says CCRAS

Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

US FDA approves first gene therapy for paediatric patients with Sanfilippo syndrome type A

US FDA approves first gene therapy for paediatric patients with Sanfilippo syndrome type A

Technology and accessibility are key to growth of advanced treatment of heart diseases, says expert

Technology and accessibility are key to growth of advanced treatment of heart diseases, says expert